AbbVie received FDA approval for Decnupaz (pivekimab sunirine), a CD123-targeting antibody-drug conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval follows AbbVie’s acquisition of ImmunoGen, positioning the asset as another ADC win for a portfolio built around targeting rare, aggressive hematologic malignancies. The decision is supported by data from the global Cadenza study, expanding AbbVie’s ADC footprint and reinforcing CD123 as a tractable therapeutic target. For BPDCN, a disease with limited treatment options and high unmet need, the approval represents a new U.S. standard candidate. Beyond the immediate clinical impact, the approval adds to regulatory validation for ADCs sourced from acquired pipelines, shaping how large pharma continues to reallocate capital across next-wave oncology modalities.